Not logged in In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment Sun, Liu; Eijgenraam, Tim R.; Amilon, Carl; Janzen, David; Hansson, Kenny M.; Kubli, Dieter A.; Spater, Daniela; Mullick, Adam E.; van der Meer, Peter; Teixeira, Vivian Oliveira Nunes; Sillje, Herman H. W. Share Save
Share Save
Early Clinical Experience With AZD4831, A Novel Myeloperoxidase Inhibitor, Developed for Patients With Heart Failure With Preserved Ejection Fraction Nelander, Karin; Lagerstrom-Fermer, Maria; Amilon, Carl; Michaelsson, Erik; Heijer, Maria; Kjaer, Magnus; Russell, Muir; Han, David; Lindstedt, Eva-Lotte; Whatling, Carl; Gan, Li-Ming; Ericsson, Hans Share Save
Discovery and Early Clinical Development of an Inhibitor of 5-Lipoxygenase Activating Protein (AZD5718) for Treatment of Coronary Artery Disease Pettersen, Daniel; Broddefalk, Johan; Emtenas, Hans; Hayes, Martin A.; Lemurell, Malin; Swanson, Marianne; Ulander, Johan; Whatling, Carl; Amilon, Carl; Ericsson, Hans; Eriksson, Annika Westin; Granberg, Kenneth; Plowright, Alleyn T.; Shamovsky, Igor; Dellsen, Anita; Sundqvist, Monica; Nagard, Mats; Lindstedt, Eva-Lotte Share Save
Share Save
Share Save
Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator Erlandsson, Fredrik; Albayaty, Muna; Chialda, Ligia; Ericsson, Hans; Amilon, Carl; Nelander, Karin; Jansson-Lofmark, Rasmus; Wernevik, Linda; Kjaer, Magnus; Bamberg, Krister; Hartleib-Geschwindner, Judith Share Save
Share Save
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
